About Vaxxas
Vaxxas is a company based in Sydney (Australia) founded in 2010. Vaxxas has raised $108.48 million across 9 funding rounds from investors including Gates Foundation, HHS and Government of Australia. Vaxxas offers products and services including HD-MAP Technology. Vaxxas operates in a competitive market with competitors including Valeritas, scPharmaceuticals, Sirnaomics, Crossject and Arcturus Therapeutics, among others.
- Headquarter Sydney, Australia
-
Sectors
TechnologyHealthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Vaxxas, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$108.48 M (USD)
in 9 rounds
-
Latest Funding Round
$49.22 M (USD), Series D
Aug 25, 2025
-
Investors
Gates Foundation
& 10 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Vaxxas
Vaxxas offers a comprehensive portfolio of products and services, including HD-MAP Technology.
Provides needle-free vaccine delivery via skin microprojections for enhanced immune response.
People of Vaxxas
Unlock access to complete
Unlock access to complete
Funding Insights of Vaxxas
Vaxxas has successfully raised a total of $108.48M across 9 strategic funding rounds. The most recent funding activity was a Series D round of $49.22 million completed in August 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Vaxxas
Vaxxas has secured backing from 11 investors, including venture fund and institutional investors. Prominent investors backing the company include Gates Foundation, HHS and Government of Australia.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm offering growth equity and credit for technology and healthcare companies.
|
Locked | Locked | Locked | |
|
UniQuest is engaged in commercialising intellectual property and innovation.
|
Locked | Locked | Locked | |
|
Seed & Early stage Life-Sciences focused VC Firm investing primarily in Australia
|
Locked | Locked | Locked |
Investor details for Vaxxas
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Vaxxas
Investment portfolio details for Vaxxas
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Vaxxas
Detailed financials for Vaxxas
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Vaxxas Comparisons
Peer comparison for Vaxxas
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Vaxxas
Vaxxas operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Valeritas, scPharmaceuticals, Sirnaomics, Crossject and Arcturus Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Wearable insulin patch pumps are developed for transdermal delivery.
|
|
| Locked | Locked | Locked |
Provider of a device for subcutaneous drug delivery for the treatment of bacterial infections and heart failure
|
|
| Locked | Locked | Locked |
RNA-based therapeutics for cancer and fibrosis are developed.
|
|
| Locked | Locked | Locked |
Needle-free self-injectable drugs
|
|
| Locked | Locked | Locked |
RNAi technologies are developed for treating rare orphan diseases.
|
|
| Locked | Locked | Locked |
Wearable insulin delivery patches are developed for mealtime dosing.
|
Detailed competitors of Vaxxas
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Vaxxas
Complete news archive for Vaxxas
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Vaxxas
Vaxxas was founded in 2010 and raised its 1st funding round 1 year after it was founded.
Vaxxas is headquartered in Sydney, Australia. It is registered at Sydney, New South Wales, Australia.
Vaxxas is a funded company, having raised a total of $108.48M across 9 funding rounds to date.
Vaxxas was founded in 2010 in Sydney, Australia, within the biotechnology sector. Vaccines targeting cancer and infectious diseases are developed through a proprietary HD-MAP platform, which enables small-patch delivery. Immune responses are enhanced, and thermostability is achieved for applications in oncology and infectious disease prevention. Operations focus on initial vaccine advancements for global health needs.
Vaxxas's top competitors include scPharmaceuticals, Sirnaomics and Arcturus Therapeutics.
Vaxxas offers HD-MAP Technology.
Vaxxas has 11 investors. Key investors include Gates Foundation, HHS, Government of Australia, OneVentures, and UniQuest.